CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-14 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −140 | $81.14 | $11K | 14,072 |
| 2021-10-14 | Kassberg Thomas Richard CBO & EVP | Sale | −286 | $81.14 | $23K | 216,266 |
| 2021-10-14 | Parschauer Karah Herdman EVP and General Counsel | Sale | −310 | $81.14 | $25K | 28,358 |
| 2021-10-14 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −853 | $81.00 | $69K | 594,347 |
| 2021-10-14 | Pinion John Richard See Remarks | Sale | −358 | $81.14 | $29K | 49,764 |
| 2021-10-14 | Dier Mardi CFO & Executive Vice President | Sale | −3,261 | $81.16 | $265K | 38,762 |
| 2021-10-12 | Dier Mardi CFO & Executive Vice President | Sale | −3,477 | $82.79 | $288K | 42,023 |
| 2021-09-30 | Kassberg Thomas Richard CBO & EVP | Option exercise | +109,734 | $0.31 | $34K | 216,552 |
| 2021-09-30 | Kassberg Thomas Richard CBO & EVP | Option exercise · Stock Option (Right to Buy) | −109,734 | 0 | ||
| 2021-09-13 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Gift | −819 | 14,212 | ||
| 2021-09-08 | Parschauer Karah Herdman EVP and General Counsel | Option exercise | +7,336 | $54.50 | $400K | 36,004 |
| 2021-09-08 | Parschauer Karah Herdman EVP and General Counsel | Sale | −7,336 | $100.65 | $738K | 28,668 |
| 2021-09-08 | Parschauer Karah Herdman EVP and General Counsel | Option exercise · Stock Option (Right to Buy) | −7,336 | 17,664 | ||
| 2021-09-02 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise | +2,500 | $55.00 | $138K | 41,275 |
| 2021-09-02 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −2,500 | $100.18 | $250K | 38,775 |
| 2021-09-02 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 53,000 | ||
| 2021-09-01 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise | +2,500 | $55.00 | $138K | 41,275 |
| 2021-09-01 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −2,500 | $100.03 | $250K | 38,775 |
| 2021-09-01 | Bedrosian Camille L EVP and Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 55,500 | ||
| 2021-07-06 | Harris Erik EVP & Chief Commercial Officer | Sale | −375 | $91.53 | $34K | 25,333 |
Page 18 of 21 · 410 trades